Lactobacillus paracasei-derived extracellular vesicles alleviate neutrophilic asthma by inhibiting the JNK pathway in airway epithelium

DOI Web Site Web Site 参考文献46件
  • Sim Soyoon
    Department of Allergy and Clinical Immunology, Ajou University School of Medicine Department of Biomedical Science, Graduate School of Ajou University
  • Park Hyeon Ju
    MD Healthcare Inc.
  • Kim Yoon-Keun
    MD Healthcare Inc.
  • Choi Youngwoo
    Department of Biomaterials Science, College of Natural Resources and Life Science, Pusan National University
  • Park Hae-Sim
    Department of Allergy and Clinical Immunology, Ajou University School of Medicine Department of Biomedical Science, Graduate School of Ajou University

書誌事項

タイトル別名
  • <i>Lactobacillus paracasei</i>-derived extracellular vesicles alleviate neutrophilic asthma by inhibiting the JNK pathway in airway epithelium

抄録

<p>Background: Lactobacillus paracasei has been known to reduce airway resistance and inflammation in asthma. However, the therapeutic effect of its extracellular vesicles (EVs) in patients with asthma remains unclear.</p><p>Methods: To validate the clinical relevance of L. paracasei-derived EVs (LpEV) in asthma, the composition of gut microbial EVs was verified by metagenomics in LPS-induced C57BL/6 mice. The components of proteins and metabolites in LpEV were identified by peptide mass fingerprinting and metabolomic analysis. The serum levels of specific IgG1 or IgG4 antibodies to LpEV were compared by ELISA between patients with eosinophilic asthma (EA, n = 10) and those with neutrophilic asthma (NA, n = 10) as well as with healthy controls (HCs, n = 10). Finally, therapeutic effects of LpEV and their metabolites in asthma were validated in vivo/in vitro.</p><p>Results: Significantly lower proportions of EVs derived from Lactobacillus at the genus level were noted in mice with NA than in control mice. Moreover, the serum levels of LpEV-specific IgG4, but not IgG1, were lower in patients with NA than in those with EA or in HCs and positively correlated with FEV1 (%) values. In addition, oral administration of LpEV reduced airway resistance and inflammation in mice with NA. Finally, LpEV and their 3 metabolites (dodecanoic acid, palmitoleic acid, and D-(-)-tagatose) significantly inhibited JNK phosphorylation/IL-8 production in airway epithelium in vitro.</p><p>Conclusions: These findings suggest that LpEV may have a therapeutic potential targeting NA by suppressing the JNK pathway and proinflammatory cytokine production in airway epithelium.</p>

収録刊行物

参考文献 (46)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ